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Introductory paragraph
Spatial heterogeneity of transcriptional and genetic markers between physically isolated 
biopsies of a single patient’s tumor poses major barriers to the identification of biomarkers, 
and the development of targeted therapies effective against the entire tumor. We analyzed 
spatial heterogeneity data from 35 patients with multi-regional biopsies using a combination 
of transcriptomic and genomic profiles. Medulloblastomas, but not malignant gliomas, 
demonstrate spatially homogeneous transcriptomes, allowing accurate subgrouping of 
tumors from a single biopsy. Conversely, somatic mutations that impact genes suitable for 
targeted therapeutics demonstrate high levels of spatial heterogeneity in medulloblastoma, 
malignant glioma, and renal cell carcinoma. Actionable targets found in a single 
medulloblastoma biopsy are seldom clonal across the entire tumor, questioning the efficacy 
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of monotherapy against a single target. Clinical trials of targeted therapies for 
medulloblastoma should first assure the spatially ubiquitous nature of the target mutation.
Letter
Many cancer types show considerable intertumoral heterogeneity between patients1–3. 
Molecular biomarkers are intended to (i) tailor treatment intensities4,5, (ii) define oncogenic 
drivers for targeted therapies5–7, and (iii) identify diagnostic mutations (i.e. SMARCB1 in 
ATRT)8. Currently, clinical diagnoses are based on single biopsies due to the assumption of 
spatial homogeneity across tumors, however, spatial heterogeneity could lead to erroneous 
tumor classification, or selection of therapies against targets only present in a locally-
restricted subset of the tumor. These implications were recently highlighted in late-stage 
renal cell carcinoma (RCC)9,10 with highly divergent mutational profiles affecting MTOR 
and TP53, as well as demonstrating good and poor prognostic gene signatures in multi-
region biopsies derived from the same tumor10,11.
To determine the degree and clinical importance of spatial heterogeneity in 
medulloblastoma, we performed multi-regional biopsies and compared gene expression 
profiles, DNA copy number aberrations, and somatic mutations. Our cohort includes 9 
primary medulloblastomas, 16 high-grade gliomas (HGG) (10 with gene expression only12), 
and 10 kidney cancers10, each with 4–11 spatially distinct biopsies (median=6). An 
overview of the data types available for each patient is presented in Supplementary Table 1a 
and Supplementary Figure 1.
Glioblastoma13 and medulloblastoma14 each comprise four distinct molecular subgroups 
that are discerned through analysis of transcriptional data. Unsupervised hierarchical 
clustering (HCL) of expression data demonstrates that medulloblastoma biopsies form tight 
clusters apart from single samples15–20 (8/8; Fig. 1a, Supplementary Fig. 2a–b), whereas in 
HGGs (3/3) and RCCs (8/9), multi-region biopsies from single individuals cluster apart 
when combined with single samples (Supplementary Fig. 2c–f,). Overall, based on the 
standard deviation of expression, inter-tumoral differences were greater than intra-tumoral 
heterogeneity in each tumor type (Fig. 1b). Using Predictive Analysis of Microarrays 
(PAM), subtype prediction revealed that 21% (13/63) of glioblastoma multi-region samples 
diverged from the most commonly observed subtype for each patient, compared to only 2% 
(1/52) of medulloblastoma biopsies (p=0.003; Fig. 1c–e; Supplementary Figs. 3–6). 
Considering only biopsies with subgroup predictions of 100% confidence, all MB tumors 
had concordant subgroup calls between multiple biopsies (9/9) compared to only 55% of 
glioblastomas (6/11; p=0.038; Fig. 1e). We conclude that medulloblastoma can be robustly 
and reliably sub-grouped from only a single biopsy, but glioblastoma cannot.
We identified somatic copy number aberrations (CNA) using a custom pipeline based on the 
TITAN algorithm21, which is robust to high levels of normal contamination (see Methods). 
Regions of CNA were identified in all three tumor entities (Fig. 2a, Supplementary Fig. 7–8, 
Supplementary Table 1b–c), and unsupervised HCL of clonal segments showed tight 
clustering of individual biopsies in the cohort across all tumor entities (Fig. 2b, 
Supplementary Fig. 9). CNA-derived measurements of spatial heterogeneity reveal variance 
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between individuals within each tumor type (Fig. 2c). Somatic single nucleotide variants and 
indels recapitulate a similar pattern of spatial heterogeneity across tumors (Fig. 2d; 
Supplementary Table 1d). Overall, based on mutation and copy number data, none of the 
three tumor types were solely comprised of only homogeneous or heterogeneous tumors, 
rather, each have a repertoire of tumors that reside along a continuum of genetic 
heterogeneity.
This genomic complexity results from a process of clonal evolution whereby successive 
acquisition of mutations and copy number events generates genetically related 
subpopulations of cells or lineages within each tumor. We integrated CNA and mutational 
data using the EXPANDS algorithm22, in order to infer the cellular lineage composition in 
each biopsy. EXPANDS detects multiple genetically distinct co-existing subpopulations of 
cells and allows phylogenetic reconstruction of their evolutionary relationships. A cartoon 
describing the spatial distribution of genetically distinct subpopulations throughout a tumor 
(Fig. 3a) illustrates the clonal intermixing detected in many samples of the cohort (Fig. 3b–
d; Supplementary Fig. 10; Supplementary Table 1e–f). Many tumor biopsies have a major 
clone (genotype present in >70% of tumor cells) that is also detected in a minority of cells in 
other biopsies from the same tumor (i.e. are subclonal), or which is absent in other biopsies 
(e.g. biopsies 3,5,6 in RCC7 are genetically similar to some cells in biopsy 4 (4a), but not all 
cells, since 4b clusters separately; Fig. 3c). In some tumors, individual biopsies contain two 
or more cell lineages that independently accumulate distinct repertoires of mutations not 
found elsewhere in the tumor (e.g. HGG2 biopsies 1,5; Fig. 3c). The presence of multiple 
genetically distinct cellular lineages within single biopsies has previously been linked to 
poor prognosis and treatment response across a variety of cancer types23.
This surprising but common pattern of major genetic clones in one biopsy that are subclonal 
or absent in spatially distinct locations in the tumor prompted us to investigate observable 
mutation clonality across biopsies, since clonality is a key requirement of clinically-
actionable therapeutic targets24. We classified mutations into clonal and subclonal 
populations (Supplementary Fig. 11; Supplementary Table 1g), and determined whether the 
subset of damaging clonal mutations changes status between spatially-separated tumor 
biopsies. In nearly all tumors we find a predominance of clonal mutations that are subclonal 
or completely absent in additional biopsies (Fig. 4a; Supplementary Fig. 12; validation set of 
7 mutations with 96% validation rate across biopsies; Supplementary Fig. 13 and 
Supplementary Table 1h). This observation remains true when considering only driver 
events25,26,27,28 (Fig 4b; Supplementary Table 1i–k). We predict that monotherapies against 
a single target identified in a single biopsy are unlikely to show dramatic clinical effects as 
the targets are not ubiquitous, leaving untargeted clones in unsampled portions of the tumor 
free to survive and repopulate the tumor.
With the goal of improved patient treatment, the clinically relevant question is whether the 
observed level of genomic spatial heterogeneity affects actionable or driver alterations. As a 
proof of concept, we focused on a set of genes with known roles in cancer initiation/
progression29, or which have defined drug interactions30. These genes are therefore enriched 
in relevant or actionable targets in a manner unbiased towards either of the cancer types 
included (Supplementary Table 1l–m). Considering the spectrum of SNVs, indels, and 
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CNAs affecting these genes (Supplementary Fig. 14–15), we found a remarkable variety of 
patterns across tumors, including: cases with only a small set of shared alterations across 
biopsies but with many events present in single biopsies (e.g. HGG4 MET amplification); 
homogeneous tumors with many shared actionable events (e.g. HGG3); cases without 
ubiquitous actionable targets, which may require multi-agent targeted therapeutics (e.g. 
MB6); tumors lacking vulnerability to any of the considered actionable targets in a subset of 
biopsies (e.g. MB7); and tumors with alterations that may predict resistance (e.g. RCC7 
TP53 compound loss and somatic mutation).
Considering the full set of identified actionable mutations per tumor across all biopsies, we 
calculate that in each entity, an average of at least 5 biopsies are required to have an 80% 
chance of identifying at least 80% of these alterations. Lowering these measures to 50% 
would require sampling of at least 2 biopsies, with highly heterogeneous tumors needing as 
many as 4 (Fig. 5a). This is likely an underestimate, as the detection of actionable mutations 
does not plateau in most patients (Supplementary Fig. 16).
Upfront profiling of numerous tumor regions in order to reveal the full repertoire of 
actionable targets is neither practical nor likely, given the amount of sequencing required, 
thus we focused on maximizing the information derived from a minimal set of biopsies. 
Specifically, we wanted to determine how well we could predict the frequency of individual 
mutations across a tumor, given increasing number of biopsies, noting that prediction 
accuracy for mutations identified in a single fraction would be high only in very 
homogeneous tumors. We empirically determined the frequency of each alteration when 
considering all possible pairs of an increasing number of biopsies, and compared this 
observed quantity to the known frequency of the alteration in all biopsies; the difference 
between these values being the inference error of mutation frequency resulting from 
insufficient biopsies in genetically heterogeneous tumors (Supplementary Fig. 17). Taking a 
10% error rate as an acceptable threshold, we calculate for each tumor the number of 
observed mutation frequencies that fall within this range (i.e. accuracy). As expected, 
accuracy improves with increasing number of biopsies, and also reveals that brain tumors 
fall into two patterns. The first comprises more homogeneous tumors, which have fairly high 
prediction accuracy even with a low number of biopsies, while the second comprises more 
heterogenous tumors that require multiple biopsies to ensure accurate determination of 
mutation frequency (Fig. 5b). In our cohort of medulloblastomas and glioblastomas, 
considering just two biopsies per tumor enables distinction of these high vs low genetic 
heterogeneity tumors, with high specificity especially for those tumors that are highly 
heterogeneous (Fig. 5c; Supplementary Fig. 18).
While spatial heterogeneity is clearly a barrier to highly effective therapeutics against the 
entire primary tumor, the extent of heterogeneity between a primary and recurrent 
medulloblastoma31 is many fold greater (Fig. 6a, Supplementary Fig. 19). This vast 
discordance at relapse is therefore unlikely to be secondary solely to inadequate spatial 
sampling of the therapeutically-naïve primary tumor. In gliomas32 the recurrent disease 
more closely resembles the primary and only in rare cases diverges to the extent seen in 
medulloblastoma, possibly due to less complete resection success in this more diffuse and 
infiltrating tumor. Medulloblastoma is known to recur from very rare populations of cells31, 
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thus, therapeutic approaches that can eradicate such cellular lineages despite their low 
prevalence in the primary tumor are drastically needed.
Immunotherapy relies on the destruction of cancer cells based on the presence of tumor-
specific cell-surface antigens as opposed to cell autonomous somatic mutations. We 
examined expression of the antigens/genes for which chimeric antigen receptor T-cells or 
monoclonal antibodies already exist33–43, and demonstrate a remarkable consistency of 
expression across multi-regional biopsies, which contrasts highly to the inhomogeneity of 
somatic mutations across fractions in the same set of tumors. This was the case in all 
medulloblastomas examined, including those with high levels of genetic heterogeneity and 
in which targeted therapy would be problematic (Fig. 6b; Supplementary Fig. 20)33–43. 
Homogeneity of the transcriptome versus heterogeneity of somatic mutations in our MB 
cohort suggests that targeted immunotherapeutic approaches could overcome the hurdle of 
spatial genetic heterogeneity.
The vast majority of brain tumor patients have their tumor classified from a single tumor 
biopsy, which may be adequate for medulloblastoma, but not for glioblastoma patients. The 
extent of spatial heterogeneity of somatic mutations observed in our cohort suggests that 
clinical trials of molecularly targeted therapy should first assess the ubiquitous distribution 
of the target. The lack of clonal actionable driver mutations ubiquitously present across all 
regions of a given brain tumor suggest that monotherapies targeting a single gene from a 
single biopsy are unlikely to have dramatic effects to improve the lives of brain tumor 
patients.
Materials and Methods
Patients and samples
Multi-region tumor biopsies and clinical data were gathered for 35 tumors (9 primary 
medulloblastomas, 16 high-grade gliomas (HGG) (10 with gene expression only12), and 10 
kidney cancers10); peripheral blood samples were included as germline (GL) controls for all 
cases with exome sequencing. All multi-region biopsies for unpublished cases were obtained 
in situ during tumor resection, by mimicking the previous sample preparation conditions of 
published cases to the best of our knowledge. Medulloblastoma tumors are similar in size to 
glioblastomas, with an average diameter of 8–12cm; biopsies were taken as far apart as 
possible by the surgeon. Renal cancers, due to their localization in the abdomen may be 
larger in size. Detailed information on multi-region tumor samples is provided in 
Supplementary Table 1a and Supplementary Figure 1. All patient material and clinical 
information were obtained after receiving informed consent and was approved by the 
institutional review boards of the contributing institutions. DNA and RNA extractions were 
performed as previously described16. RNA quality was assessed on a 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Only high-quality RNA (RNA integrity number 
≥7) was included for further studies.
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Gene expression profiling
Expression profiling was conducted on eight MB and three HGG multi-region biopsies 
totaling 72 biopsies with a median number of 6 multi-region biopsies per primary (range 4–
9). Affymetrix HU133 Plus 2.0 microarrays were used for HGG samples and Affymetrix 
Gene 1.1 ST array (Affymetrix, Santa Clara, CA) was used for MB samples to ensure that 
these multi-region biopsies could be compared to published data sets15–17,20. Microarrays 
were processed according to the manufacturer’s guidelines. Raw data was normalized using 
a transcript-level robust multi-array average (RMA) algorithm44, and subsequently clustered 
using unsupervised HCL (Pearson’s Dissimilarity – average linkage) in Partek Genomics 
Suite. The molecular classification of the multi-region biopsy samples was performed using 
a class prediction algorithm, Prediction Analysis for Microarrays (PAM)45, as implemented 
in the pamr package (v 1.51). Markers for GBM subtypes were obtained from the Verhaak 
classifier13. We note that classification was performed for the GBM samples only, thus 
excluding HGG1. Subgroup-specific markers for MB were identified based on one-way 
analysis of variance (ANOVA) with multiple hypothesis correction by the Bonferroni 
method in previously published datasets with known subgroup affiliation46. Based on the 
misclassification error values in core GBM13 and MB15–17 training datasets (Supplementary 
Fig. 6), threshold values of 1.75 and 1 were chosen for multi-region samples from 
published12 and unpublished GBM and MB patients, respectively. The published GBM 
dataset12 was quantile normalized using Partek Genomics Suite. Predicted subtypes or 
subgroups with confidence probabilities higher than established thresholds46 were 
considered bona fide subgroup assignments. Samples with less than 500 ng of remaining 
RNA were analyzed using NanoString as previously described46. MB3 was exclusively 
analyzed using NanoString since only limited amounts of RNA were available for all multi-
region biopsies. NanoString counts were normalized to the three housekeeping genes 
(GAPDH, ACTB and LDHA). Dot plots and PCA based on normalized NanoString calls 
were prepared using the R-statistical environment (v2.15.1). Pearson correlation was used to 
determine the correlation of marker gene expression for each biopsy per patient (intra-tumor 
comparison) and between each biopsy and all others samples from different patients of the 
same subgroups (inter-tumor comparison). Wilcoxon rank sum test was used to infer intra- 
and inter-tumor marker gene expression differences in a subgroup-specific fashion.
A previously published dataset of nine multi-region RCC samples9 profiled using the 
Affymetrix Human Gene 1.0 ST array was included in the analysis as well as two RCC 
datasets18,19 with 53 and 29 single RCC samples, respectively. The RCC expression datasets 
have been processed together in R (v3.1.1) with the oligo package (rma normalization) and 
the combat package has been used for batch effect correction. Unsupervised HCL (Pearson’s 
Dissimilarity – average linkage) has been performed using the Partek Genomics Suite.
The Gene Expression Omnibus accession numbers for the previously-unplublished gene 
expression data are GSE62802 (HGG samples) and GSE62803 (MB samples).
Whole-Exome Sequencing
DNA libraries (MB1-5) from multi-region samples were exome captured using Agilent 
SureSelect V5+UTR probes, followed by 8 cycles of PCR and then paired-end 75 base reads 
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were sequenced over 2 lanes on an Illumina HiSeq 2000 instrument per pool of 6 libraries. 
Reads were aligned to the human reference genome hg19a using the Burrows-Wheeler 
Aligner (BWA) (version 0.5.7)47. Two lanes were merged with duplicates marked using 
Picard Tools (version 1.71). Additional samples (MB6/7, HGG1-5) were subjected to paired-
end library construction using Illumina’s Nextera Rapid Capture Exome (RCE) kit. 
Captured exome DNA sequences were then sequenced on Illumina HiSeq 2000 (rapid-run 
mode) for 100-bp paired-end reads. We used FASTX toolkit to remove adaptor sequences 
and to trim low quality reads. Quality trimmed reads were then aligned to the human 
reference genome (hg19) using BWA (version 0.5.9)47. Genome Analysis Toolkit (GATK)48 
was used for indel realignment. Duplicate reads were then marked using Picard to be able to 
exclude them further in our analysis. The Toronto datasets are available under accession 
numbers EGAD00001000723 and EGAS00001001014.
Somatic SNV detection and filtering
SNVs were called exome-wide using samtools mpileup (v0.1.7), and indels were called 
using VarScan. Stringent filtering was performed requiring no reads in the germline sample 
supporting a SNV to ensure conservative selection of somatic events. Variants with sufficient 
coverage (≥10) were further annotated using Annovar49 (table_annovar.pl; RefSeq gene 
annotations, amino acid change annotation, SIFT, PolyPhen, LRT, and MutationTaster 
scores, PhyloP and GERP++ conservation scores, dbSNP identifiers, 1000 Genomes Project 
allele frequencies, NHLBI-ESP 6500 exome project allele frequencies).
Mutation Validation
A subset of somatic mutations were validated using PCR amplification from all tumor 
biopsies, matched germline, and a healthy control sample. Regions of interest were 
amplified from genomic DNA using primers flanking each SNV (Supplementary Table 1h,n) 
using Q5 High-Fidelity DNA polymerase (NEB). PCR specificity was determined by 
agarose gel electrophoresis followed gel extraction of specific bands using Gel 
Extraction/PCR Clean-up kit (Qiagen) following manufacturer instructions. Purified 
amplicons were sequenced using Sanger sequencing, and traces reviewed manually for the 
expected presence or absence of the mutated base.
Droplet digital PCR
For the validation and quantification of the frequency of the PIK3CA SNV detected in MB3, 
we used droplet digital PCR (ddPCR), since Sanger traces were of poor quality in the region 
of interest. Genomic DNA from 6 spatially distinct biopsies from MB3 as well as matched 
germline and a healthy donor control were used in the assay. The PIK3CA mutation (chr 
3:178936091 G>A) was validated by using the PrimePCR ddPCR mutation assay kit, 
PIK3CA p.E545K, human (Biorad, dHsaCP2000075 (mutant, FAM) and dHsaCP2000076 
(Wt, VIC)), accordingly to manufacturer instructions. Fluorescence measurement using 
QX100 ddPCR droplet reader (Biorad) was used to detect the presence of mutant and 
wildtype alleles. QuantaSoft Analysis software (Biorad) was used in the quantification.
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Copy number analysis
TITAN21 estimates the cellular prevalence of tumor cell populations (lineages) based on a 
user-defined number of clonal clusters, and user-defined ploidy estimation. Thus, 20 runs of 
TITAN were performed for each exome, with cluster numbers 1 to 10 (representing one 
clonal lineage through to 10 co-existing clonal lineages with distinct genotypes), and ploidy 
set to either 2 or 4. Copy number segments from the 20 parameter combinations were 
analyzed and merged into larger segments if they were on the same chromosome arm, were 
<10Mb apart, and had the same state (loss or gain). Merged results from each of the 20 
parameter combinations for each biopsy were compared in order to select the optimal 
parameter combination as the highest scoring considering the following criteria:
maximize the largest contig size
maximize the median contig size
minimize the number of contigs
minimize the number of clonal clusters
The parameter combination with the largest x value was selected as optimal, where:
L = largest contig size (Gb)
M = median contig size (Gb)
T = total number of contigs
C = clonal clusters
We next assessed the prevalence of copy number segments (loss or gain) identified in the 
best parameter combination of a unique biopsy (i.e. target segments), using either all 
segments or clonal segments only (logratio ≥ |0.2|). A target segment was considered as 
found in another biopsy from the same tumor if any of the 20 parameter combinations 
contained a segment with the same state (loss or gain), and whose span had a minimum 
reciprocal overlap of at least 70% with the target segment.
Concordance of driver regions of loss and gain in the RCC tumor cohort was performed for 
our calls and the published data9. With our computational approach, we achieved a 97% 
concordance when comparing to the manual curation performed previously9, indicating that 
this method is specific and sensitive despite a high level of normal cell contamination in 
these tumors. Conversely, compared to our results for the subset of copy number gains and 
losses identified in Gerlinger et al., 2014, the manual curation shows an 89% concordance to 
the TITAN pipeline, indicating that our approach is more sensitive, and that the homogeneity 
of certain copy number driver events may be greater than previously estimated 
(Supplementary Table 1c). Finally, our approach is applicable genome-wide and across 
tumor types in a highly parallel fashion.
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SNV Classification using mclust
Variant allele frequencies (VAF) of somatic SNVs were classified into distinct clusters using 
the R package mclust50, which uses finite mixture estimation via iterative Expectation 
Maximization steps (EM) and the Bayesian Information Criterion (BIC). Each cluster is 
manually categorized as “homozygous”, “clonal”, or “subclonal”, depending on the cluster 
VAF and the uncertainty separating it from the next cluster, and taking into account the 
biopsy tumor cell content value reported by TITAN. Multiple subclonal populations are 
numbered sequentially, starting with the most highly prevalent population. Clonal and 
subclonal mutation details per biopsy are summarized in Supplementary Table 1d,g.
Phylogenetic reconstruction from combined SNV and CNV data
We combined copy number and LOH information derived from TITAN (including the clonal 
and subclonal events identified in the best parameter combination run for each biopsy), as 
well as somatic mutations and SNPs in areas of LOH, to infer tumor phylogenies using 
EXPANDS22. EXPANDS v1.7.2 was run with the runExPANdS function. All parameters 
were set to default with the exception of maxScore, which was lowered to 1.5 in order to 
reduce the false positive rate of subpopulation detection. Only subpopulations with a 
minimum size (cellular frequency) of 0.1 were considered. Mutations that could not be 
assigned to a high confidence subpopulation were discarded, so that no ambiguous 
assignments were made. In addition, ambiguous subpopulations (i.e. groups of mutations 
and copy number events) were dropped from the analysis. Mutations are assigned to all 
nested subpopulations (i.e. if a mutation is found in a subpopulation of cells at a high 
frequency of 0.8, it will also be assigned to “daughter” subpopulations, for instance of 
frequency 0.5), to report the assignment of every mutation to all detected subpopulations in 
all biopsies of the tumor (assuming that the mutation could be assigned unambiguously as 
mentioned above; Supplementary Table 1f).
Phylogenetic relationships between the subpopulations inferred by the EXPANDS algorithm 
in all biopsies per patient were generated using both SNV and copy number segments. The 
Manhattan distance metric was used to calculate pairwise distances between all pairs of 
biopsies based on this data, and a complete linkage hierarchical clustering was performed to 
generate phylogenies. Germline-rooted trees were generated using the as.phylo R function 
from the ape package.
Error inference of actionable genetic alterations
In order to perform an analysis of genetic heterogeneity affecting actionable and putative 
driver genes in a way that is unbiased to either of the tumor types, we opted to use general 
lists of known cancer drivers and drugable genes. Sets of genes known to be drivers in GBM, 
MB, and RCC tumors come from studies of different cohort sizes, with sometimes unknown 
subgroup affiliation, and thus are not equally comprehensive. To overcome this, we used a 
list of genes of interest that includes putative driver genes found in the Cancer Gene Census 
database29 (n=572) and actionable genes from the Drug-Gene Interaction Database30 (n=426 
genes) (Supplementary Table 1l–m).
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Oncoprint plots (R package ComplexHeatmap v1.6.0) were built for the combination list of 
these genes for all tumors, using (a) clonal mutations and indels and (b) clonal mutations 
and indels plus high-level copy number aberrations (>4 copies gained; homozygous loss). 
Manual review of results revealed that absence of clonal somatic mutations in subsets of 
biopsies is not explained by concordant copy number loss. Since not all biopsies had copy 
number data, further analyses were performed using results from strategy (a) in order to 
maximize the number of usable biopsies per tumor.
Driver event lists
The MB CNA driver events in Supplementary Table 1i,j and Figure 4b are mainly taken 
from Shih et al.27 plus a subset of the mostly highly recurrent genes listed in Northcott et 
al.25. The HGG chromosome arm and recurrent driver genes events were retrieved from 
Sturm et al.26 (Table 1 and 2 of Reference 26). RCC chromosome arm and gene-level driver 
events were retrieved from the ccRCC TCGA paper28 (Sup Fig 22 threshold FDR q-value< 
10−15 and Table S4, q-value threshold 0.05). Cancer cell fraction values presented in 
Supplementary Figure 10b for driver mutations were calculated as previously described51:
where CCF=cancer cell fraction, VAF=variant allele frequency, CN=copy number at the 
mutation, purity=tumor purity as calculated by EXPANDS.
Accuracy of mutation frequency detection
We calculate the inferred error of the prevalence of each mutation across biopsies using a 
subsampling approach. In each tumor, given a subset of biopsies from 1 to n (where n = total 
biopsies per tumor), the frequency of each identified mutation in the biopsies sampled is 
calculated as fo. This value is subtracted from the “ground truth” expected frequency for that 
mutation across all n biopsies (fe). When the observed and expected values are identical, 
then the inferred error (fe – fo) is 0. In the majority of tumors, there is a predominance of 
genes with mutations in single biopsies, leading to negative values of error for many genes 
as the frequency of the mutation is often overestimated (Supplemental Fig. 17). In contrast, 
genes that are present in all but one or two biopsies will often have an error value over 0, as 
their frequency can be underestimated.
The likelihood of being within +/−0.1 of 0 (i.e. close to perfect accuracy given the data from 
all biopsies) is calculated as the proportion of genes at each sampling of 1:n biopsies where 
the error rate was within those bounds. For instance, we sample all possible combinations of 
a certain number of biopsies from the total number of biopsies, and in each case calculate 
the inferred error of each detected mutation’s prevalence. The proportion of the total set of 
error values < |0.1| is the likelihood of a correct interpretation of mutation frequency given 
that number of biopsies (Fig. 5b).
Genetic heterogeneity estimation from two biopsies
To address the practical issue of estimating genetic heterogeneity from a minimum number 
of informative biopsies, we implemented a simple metric of the proportion of mutated genes 
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in a set of 2 biopsies that was ubiquitous (i.e. present in 2 of 2 biopsies). The mean value of 
all pairs of biopsies from a total of n biopsies per tumor showed a strong divergence in HGG 
and MB tumors, with high- vs low-variability tumors well separated (Fig. 5c). These were 
the same tumors that scored as high vs low variability based on the accuracy metric 
described above.
We also observed clear separation of these two classes using the R package mclust 
(Supplementary Fig. 18a), which models univariate mixtures of Gaussian distributions (i.e. 
corresponding to a mixture of high and low genetic variance brain tumors) via Expectation-
Maximization and the Bayesian Information Criterion50. Choosing two thresholds from the 
mclust density peaks (low=0.55, high=0.75), we calculated the accuracy of classifying high-
variance vs low-variance tumors based on a single pair of biopsies, and observed that high-
variance tumors in particular have a high true positive and low false positive classification 
rate (Supplementary Figure 18b). I.e. based on this metric, the vast majority of pairs of 
biopsies from tumors with high genetic heterogeneity have a low percentage of gene 
mutations found in both biopsies, such that they are always classified as heterogeneous 
tumors, and almost never as homogeneous tumors.
Expression analysis of immunotherapeutic targets in MB tumors
Microarray expression data from the Affymetrix Gene 1.1 ST array (Affymetrix, Santa 
Clara, CA) for the MB samples were analyzed in the R environment (v3.1.1).
We used the affy package (v1.44.0) and the custom CDF hugene11sthsensgcdf (v19.0.0) to 
summarize the expression of 21641 Ensembl (ENSG) genes and process the data. 
Expression data was normalized using the rma method.
Spatial genetic variance vs post-treatment clonal evolution
To directly measure the relative contribution of spatial heterogeneity versus clonal evolution 
induced by treatment, we utilized our previously published cohort of matched pre- and post-
therapeutic MB samples31. This comparison shows that in MB, the amount of divergence 
observed between primary and relapse compartments far exceeds spatial genetic variance in 
the primary tumor.
To assess whether the observed divergence between primary and recurrent MB is greater 
than the observed divergence between intra-tumoral biopsies, we re-analyzed the 14 
primary-relapse tumor WGS samples with matched germline using the same pipeline as 
presented above. Briefly, mutations were called using samtools mpileup, filtered stringently 
against the germline, and shortlisted to those mutations that have at least 10 reads coverage 
in both the primary and recurrent samples, and are in areas of normal copy number and 
LOH. Since the samples in this work are exomes, we restricted the analysis of the primary-
relapse samples to the same exonic regions. After removing the major analysis pipeline 
differences, we addressed differences in depth of coverage. The exome libraries were 
sequenced to an average of 60X, while the WGS samples were sequenced to 30X coverage. 
Thus, our ability to assess similarity between regions in the exome libraries is more sensitive 
to subclonal events present at low levels (and therefore preferentially detectable by exome 
seq and not by WGS). We addressed this bias by restricting the analysis to clonal events in 
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the exomes, as clonal mutations are detectable both in exomes and genomes. To verify that 
this was a reasonable assumption, we compared the VAF of mutations found in the exomes 
to those found in matched WGS data generated from the same samples, but sequenced at 
30X coverage. Matched WGS samples are available for biopsy 1 in each MB tumor with 
multi-regional profiling. In all cases, we found that >75% of mutations with a VAF < 0.18 in 
the MB exomes were not found in the matched genomes sequenced from the same samples, 
indicating that subclonal events are typically not well profiled at the shallower depths of a 
genomic library. Therefore we restricted our analysis to clonal events in both the exomes and 
genomes.
Focusing on the clonal and homozygous events detectable in both exome and genome data, 
we hypothesized that any differences between primary and relapse samples that are greater 
than the differences expected from different biopsies in a primary tumor would be largely 
attributable to clonal evolution as a consequence of therapy. To see if the data support this 
conclusion, we used the mutations in each biopsy to measure pairwise concordance between 
all biopsies of individual tumors. Concordance is measured as the number of mutations in 
common between two biopsies, as a fraction of the total number of mutations present in 
both. In parallel, we used the mutations in the primary and relapse samples to measure 
pairwise concordance values between disease compartments. As a positive control, we 
compared the inter-biopsy and inter-compartmental concordance values of an adult GBM 
sample with multiple biopsies profiled before and after therapy (Patient 17 from 
reference32).
In MB samples we found a mean pairwise concordance of 0.3903 between biopsies of the 
same tumor, nearly an order of magnitude higher than the mean concordance (0.03852) 
observed between disease compartments (Wilcoxon Rank Sum test p-value < 2.2e–16). One 
sample stood out as an outlier (MB-REC-04), and we note that in this case the tumor was a 
Group4 local recurrence. This unusual pattern of recurrence for a Group4 tumor may 
indicate that the primary mass was sub-totally resected rather than grossly resected, 
explaining the higher similarity of the recurrent compartment to the primary.
In the case of the adult GBM patient (Patient17) with multi-regionally sampled primary (3 
regions; low-grade glioma) and recurrent disease (4 regions; high-grade glioma), we found 
the same trend: the primary-relapse mean concordance of 0.01506 was an order of 
magnitude smaller than the mean intra-biopsy concordance of 0.5036 (Wilcoxon Rank Sum 
test p-value = 0.0001406). There was no significant difference between the primary-relapse 
MB concordance and the primary-relapse GBM concordance observed in Patient17 
(Wilcoxon Rank Sum test p-value = 0.5458). Similarly, there was no significant difference 
between the regional biopsies in GBM vs MB (Wilcoxon Rank Sum test p-value = 0.09926).
Finally, the primary-relapse divergence calculated using reprocessed data from Patient17 
was on par with that initially presented in the glioma paper41, thus we included, for visual 
comparison, all the primary-relapse values for the glioma cohort in Figure 6a (middle panel; 
Johnson et al, 2014; values directly derived from Supplementary Table 432).
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Statistical analysis
All statistical analyses were performed in the R statistical environment. Comparisons of 
categorical variables between entity types were performed using the two-sided Fisher’s exact 
test. Comparisons of distributions were performed using the Welch two-sample t-test 
(parametric) or the Wilcoxon Rank Sum test (non-parametric). P-values <0.05 were 
considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Medulloblastomas, but not glioblastomas, show reliable transcriptome-based subgroup 
prediction
(a) Unsupervised HCL using 1,000 high–SD transcripts of eight multi-region 
medulloblastoma (MB) samples combined with single biopsies (n=334) demonstrates tight 
clustering of matched multi-region MB samples across subgroups. (b) Box plot of the top 
2000 SD-transcript values determined on an intra- and inter-tumor level in MB, HGG and 
RCC. (c) Principal component analysis (PCA) using 22 MB subgroup marker genes 
confirms a low degree of transcriptional intra-tumoral heterogeneity exemplified in MB3. 
Multi-region biopsy numbers of MB3 are indicated, and PCA was conducted with 103 single 
biopsy samples analyzed by NanoString. (d) Dot plot illustrating highly comparable marker 
gene expression in all multi-region biopsies for MB3. (e) Illustration showing GBM subtype 
and MB subgroup predictions based on Predictive Analysis of Microarrays (PAM) results. 
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SHH subgroup affiliation of MB3 (marked with a *) was inferred based on NanoString 
results. Hashed circles are biopsies with <100% prediction confidence.
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Figure 2. Variable intra-tumoral heterogeneity of somatic aberrations in all tumor entities
Genome wide analysis of copy number aberrations does not recapitulate the striking 
expression-based spatial homogeneity of MBs. (a) Copy number segments of gain (red) or 
loss (blue) are shown across the genome of three individual patients for each biopsy. (b) 
Unsupervised HCL of copy number segments show tight clustering of individual biopsies 
across all tumors in the cohort. Intra-tumoral heterogeneity measured from CNA’s (c) or 
SNVs (d), both in individual patients (top panels) and summarized by entity (lower panels) 
shows that tumors in all entities range from high spatial similarity (e.g. HGG3, MB2) to low 
(e.g. HGG1, RCC3). Similarity is measured as the binary distance between all pairs of 
tumor-matched biopsies.
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Figure 3. Spatial intermixing of clonal lineages
(a) Example cartoon of a tumor with four clonal lineages that are spatially dispersed (blue, 
green, pink, purple) demonstrates how data from three biopsies are used to build a typical 
biopsy-level phylogenetic tree as well as a subpopulation-level tree reflecting inter-mixing of 
the three detected genetic lineages. Branch tips are colored according to biopsy number and 
labeled according to biopsy number (1,2,3…) and clonal lineage (a,b,c…). Branch colors 
correspond to the cellular genotype; black squares indicate major cellular lineages (>70% of 
tumor cells in the biopsy, scaled by the largest detectable population). Note that the number 
of biopsies may not be sufficient to ‘discover’ all distinct clonal lineages (e.g. purple clone). 
(b) Biopsy-level trees of three representative tumors; MB7, HGG2, and RCC7. (c) 
Subpopulation-level trees reveal that some cellular lineages have high similarity to lineages 
in other biopsies, suggesting spatial intermixing (e.g. MB7 biopsy 1,2,3; RCC7 biopsy 4). 
Conversely, some biopsies harbor >1 distinct lineage (e.g. HGG2 biopsy 5). (d) Variant 
allele frequency (VAF) of mutations are shown along with copy number aberrations 
exclusive to or shared by pairs of biopsies or subpopulations. VAF scatter plots have a 
smoothed color density; black dots represent individual mutations. CNA events (black 
triangles) are displayed (with some jitter) if present in either compartment, or shared.
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Figure 4. Genetically distinct clonal lineages yield ON/OFF mutation patterns between spatially 
separated biopsies
(a) Non-synonymous mutations are binned into 5 categories: those clonal in all biopsies 
(Clonal); clonal in some biopsies and sub-clonal in others (Clonal/Subclonal); clonal in 
some biopsies and completely absent in others (Clonal/Absent); clonal in some biopsies, 
sub-clonal in others, and absent in others (Clonal/Subclonal/Absent); and those never 
detected as clonal (Non-Clonal). Upper panel: illustration of the most favorable clinical 
scenario in which most mutations are clonal across all biopsies (left), and the worst-case 
scenario where mutations are clonal in some biopsies but absent in others (right). Lower 
panel: Mutation patterns follow a worst-case scenario across tumor types. Tumor-specific 
polygons on radial plots indicate the proportion of mutations on each of the 5 axes, with 
polygon centers marked by a black circle. (b) Barplots of the proportion of driver mutations/
indels (top panel) or CNAs (lower panel) that are found in every biopsy of a given tumor 
(i.e. trunk events) when considering the clonal and subclonal or only clonal driver events. 
The absolute numbers are shown above the bars.
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Figure 5. Quantification of variable genetic heterogeneity across tumor entities
(a) Considering all mutated genes (from the list of actionable targets) identified in each 
tumor across all biopsies, individual tumors require an average of 5 biopsies to have an 80% 
likelihood of recovering 80% of the known mutated genes (top panel). At least 2 biopsies are 
required to achieve a 50% likelihood of recovering 50% of mutated genes (bottom panel). 
Small points: individual samples; large points: tumor entity median. (b) The likelihood of 
correctly inferring the frequency of a mutation in the whole tumor depends on the number of 
biopsies sampled, and whether the tumor is more or less genetically homogeneous. The 
accuracy of frequency prediction for brain tumors shows a bi-modal pattern, with low 
genetic variance tumors having a higher accuracy (>0.6) even with few biopsies, while high 
genetic variance tumors require at least 5 biopsies to achieve the same confidence (HGG and 
MB panels). RCC tumors additionally show an intermediate pattern. Accuracy is measured 
as the proportion of times that a gene’s observed frequency in a selection of biopsies is 
within 10% of the known frequency across all biopsies. Lines represent a Loess fit to the 
points per tumor, with a 95% confidence interval (grey outline). (c) Considering a random 
selection of 2 biopsies, patients are ranked using the proportion of mutated genes (from the 
actionable target list) that are present in both biopsies. Patients with genetically 
heterogeneous tumors have median values <0.2. Points represent the median value of all 
possible biopsy pairs per patient.
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Figure 6. Genetic heterogeneity at recurrence greatly exceeds spatial heterogeneity in MB
(a) The genetic concordance of pre- vs post-therapy biopsies (from Morrissy et al, 2016) is 
an order of magnitude lower than up-front genetic spatial heterogeneity, in MB samples 
(p<10−16; Welch two sample t-test; n=14 primary-recurrence pairs; n=158 spatial 
comparisons from 7 tumors). HGG tumors in our cohort showed a similar overall 
distribution of spatial heterogeneity (n=92 comparisons from 4 tumors), and not 
dramatically different compared to the low concordance of low-grade gliomas (LGG) to 
HGG post-therapy41 (n=23 glioma primary-relapse pairs, Johnson et al, 2014). One LGG 
relapse to HGG exhibited post-therapeutic genetic concordance values on par with MBs 
(p<10−4; Welch two sample t-test; n=12 primary-relapse comparisons from Patient1732; n=9 
spatial comparisons). Concordance is measured as the proportion of clonal somatic 
mutations in common between a pair of biopsies given the total number of clonal somatic 
mutations in the two samples. Width of bean plots scale with the number of measurements 
with a similar y-value, showing data distribution. Thin horizontal lines indicate individual 
observations; multiple observations with the same value are added together to form wider 
lines; thick horizontal black bars indicate averages. (b) Low expression variance is observed 
across multi-region biopsies of cell surface molecules with immunotherapies currently in 
clinical trials. This indicates that tumors with high genetic spatial heterogeneity may respond 
well to CAR T-cell or antibody-based therapy. Green points mark expression of target genes 
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in individual biopsies; long horizontal lines: median expression per tumor; lower and upper 
short horizontal lines: 25th and 75th percentiles of expression per tumor.
Morrissy et al. Page 26
Nat Genet. Author manuscript; available in PMC 2017 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
